LUPUS IN THE USA
In 2014, data from the Michigan [1] and Georgia [2] Lupus Registries were published and provided a valuable insight into the incidence and prevalence of systemic lupus erythematosus (SLE) in the United States in a population predominantly composed of Caucasians and African Americans (Table 1) . A similar Centers for Disease Control and Prevention (CDC)-funded population-based registry [3] , determined the prevalence and incidence of SLE among American Indian and Alaska Native people within the Indian Health Service clinical population. These studies overcame the shortcomings of previous epidemiologic data in the USA by using identical case definitions [meeting 4 American College of Rheumatology (ACR) criteria or a renal biopsy of lupus nephritis/end-stage renal disease or a rheumatologist's diagnosis], and a broad range of case-finding sources. The number of Hispanic and Asian patients in these three registries was small, so the CDC supported the creation of two similar lupus registries in California and New York. The recently published data from the California Lupus Surveillance Project (CLSP) [4] and the Manhattan Lupus Surveillance Program (MLSP) [5 & ] included populations with greater numbers of Asian and Hispanic patients.
Both studies reported a higher prevalence and incidence rate of SLE in women compared with men, and in African Americans compared with Caucasians, similar to the data reported from Michigan and Georgia. The diverse population allowed estimation of incidence and prevalence among Hispanics and Asians, who had a higher incidence and prevalence of SLE compared with Caucasians, but lower than African Americans (Table 1) . The diverse populations included in these two registries allowed the first reliable estimation of incidence and prevalence among the Hispanic and Asian population in the United States.
Ungprasert et al. [6] used both the SLICC and the American College of Rheumatology SLE criteria to investigate the incidence of SLE in Olmsted County, Minnesota, from 1993 to 2005. They demonstrated a higher incidence of SLE when using SLICC criteria (58 cases) compared with ACR criteria (44 cases), mostly because of cases of isolated lupus nephritis, serologic abnormalities, and nonscarring alopecia.
Furst et al. [7] evaluated the incidence and prevalence of SLE in a large national managed-care claims database in the United States using historical data. The incidence and prevalence of SLE was similar to previous estimates (Table 1) .
LUPUS WORLDWIDE
Other than the recently published data from the Michigan Lupus Epidemiology and Surveillance Registry [8] which described a 2.1-fold higher incidence of SLE among Arab-Americans compared with non-Arab Caucasians and African Americans [8] , little was known about the epidemiology of SLE among the Arab population worldwide or in the Middle East. Al Dhanhani et al. [9] studied the incidence and prevalence of SLE in the United Arab Emirates. The age-standardized incidence over the 4-year period was 8.6/100 000 per year ( Table 2 ). The incidence rates described were similar to the ones reported in the Michigan Lupus Epidemiology and Surveillance Registry for the Arab population (7.6/100 000 person-years).
In Europe, Schneider and co-workers [10] used age-specific and sex-specific claims data to estimate the incidence of SLE in the German population ( Table 2 ). The estimated incidence rates of SLE were at the lower end of other estimates from comparable European countries, with the incidence rate for German women being less than half of the French rate [11] .
Otsa et al. [12] estimated the incidence and point prevalence of SLE in Estonia by extracting SLE ICD-10 codes for individuals older than 20 years of age from the Estonian Health Insurance Fund database ( Table 2 ). The reported SLE incidence in Estonia was lower than in countries with similar prevalence, presumably because of the use of a lower age limit of 20 years as a study inclusion criterion.
In southern Sweden, Ingvarsson et al. [13] (Table 2 ) reported a decrease in the incidence rate of SLE over a period of 26 years, particularly in middle-aged women, whereas disease phenotype remained unchanged. The prevalence of SLE increased slowly over the same period.
In Denmark, Hermansen et al. [14] (Table 2 ) in an analysis of the Danish National registry reported an incidence rate for SLE of 2.35per 100 000. Sexspecific incidence rates of SLE and of lupus nephritis peaked later in life among men than among women.
The first estimates of SLE incidence and prevalence on the island of Crete were reported [15] ( Table 2 ). Although the incidence of SLE and lupus nephritis remained stable over the study period (1999-2013), prevalence increased.
A retrospective cohort study in the United Kingdom [16] (Table 2 ) using the Clinical Practice Research Datalink showed a decline in the annual SLE incidence of 1.8% whereas in contrast the prevalence increased from 64.9 per 100 000 in 1999 to 97.04 per 100 000 in 2012. There was regional variation in both incidence and prevalence. People of Afro-Caribbean ethnicity had the highest incidence and prevalence.
In a systematic review of worldwide incidence and prevalence of SLE [17 & ], the highest estimates of incidence and prevalence of SLE were in North America (23.2/100 000 and 241/100 000 personyears, respectively). Lower incidences of SLE were reported in Africa and Ukraine (0.3/100 000 personyears), and the lowest prevalence was in Northern Australia (0 cases in a sample of 847 people). Women were more frequently affected than men for every age and ethnic group. People of African ethnicity had the highest incidence and prevalence of SLE, whereas those of Caucasian ethnicity had the lowest incidence and prevalence. There appeared to be an increasing trend of SLE prevalence with time.
MORTALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS
A population-based study [18] using the National Vital Statistics System reported data on SLE deaths from 1968 through 2013. After an initial decrease between 1968 and 1975, SLE mortality increased annually for 24 years, followed by a sustained decrease for 14 years starting in 1999. On the other hand, all-cause mortality decreased throughout the study period. Residence in the West conferred the highest SLE mortality risk in all racial/ethnic groups except Caucasians, who had the highest risk in the KEY POINTS More accurate estimates of incidence and prevalence of SLE among different ethnicities and minority groups in the USA have shown a higher incidence and prevalence of SLE among Hispanics and Asians.
Despite advances in treatment, standardized mortality rates in SLE remain three times higher than in the general population with significant ethnic differences.
Cardiovascular risk in SLE varies based on ethnicity with the highest risk seen among African Americans. 
Epidemiology of lupus Stojan and Petri
South. Residence in the Northeast conferred the lowest mortality risk regardless of sex or ethnicity. Costenbader et al. [19] analyzed Medicaid claims data and reported higher SLE mortality rates per 1000 patient-years among Native American (27.52), Caucasian (20.17) , and African American (24.13) patients. Mortality rates were lower among Hispanic (7.12) or Asian (5.18) patients.
In a general population based study in the United Kingdom, SLE patients were shown to have nearly double the premature mortality risk of their peers [20] .
Lee et al. [21 & ] performed a meta-analysis of studies examining all-cause and cause-specific standard mortality rates (SMR) in SLE. All-cause SMR were increased 2.6-fold in SLE patients. The risk of mortality was significantly increased for mortality because of renal disease (SMR 4.689), cardiovascular disease (SMR 2.253), and infection (SMR 4.980), but not because of cancer (SMR 1.163).
IMPACT OF FAMILY HISTORY
A study from Denmark [22] identified hospitalized patients with SLE over a period of 36 years and coupled them with their relatives through the Civil Registration System followed by identification of twins using the Danish twin registry. Hazard ratios of SLE were high among first-degree (hazard ratio 10.3) and second-degree or third-degree relatives of SLE patients (hazard ratio 3.60). Risk of other autoimmune diseases was significantly increased both among SLE-affected first-degree (hazard ratio 2.08) and second-degree or third-degree relatives (hazard ratio 1.38).
In a separate publication [23] , same authors reported a lower SLE twin concordance in Denmark than previously reported. Among seven monozygotic, eight same-sex dizygotic and five oppositesex dizygotic twin pairs, one monozygotic and one dizygotic same-sex pair were concordant for SLE. This corresponded to proband and pairwise concordance rates of 25 and 14.3% for monozygotic twins, and proband and pairwise concordance rates of 7.7% for dizygotic twins.
IMPACT OF AGE AND SEX
The RELESSER cohort data on sex differences among SLE patients [24] showed men to be diagnosed at a more advanced age than women. Men also had more cardiovascular comorbidities and were hospitalized more frequently. Men were more likely to lose weight, have lupus nephritis, lymphadenopathy, splenomegaly, and pulmonary fibrosis. Female patients were more likely to have inflammatory rash, alopecia, Raynaud's phenomenon, and arthritis.
A prospective single-center cohort in South Korea followed 133 children and 979 adults with SLE over a period of 14 years [25] . Children with SLE had a higher number of cumulative ACR criteria and a higher adjusted mean SLE Disease Activity Index, but there was no difference in SLICC/ACR damage index. Immunosuppressants were used more frequently by children with SLE. The standardized mortality rate in pediatric SLE was 18.8, compared with 2.9 in adult SLE, a highly statistically significant difference.
MALIGNANCY RISK IN SYSTEMIC LUPUS ERYTHEMATOSUS
Several studies examined the malignancy risk among SLE patients. A retrospective nested casecontrol study [26] , which included 14 842 patients in Taiwan analyzed the risk of malignancy among SLE patients on azathioprine, cyclophosphamide, methotrexate, hydroxychloroquine, and glucocorticoids. A total of 330 patients developed a malignancy. The top five types of cancers were breast (16.9%), hematological (11.7%), colorectal (11.0%), lung (10.6%), and hepatobiliary (10.4%) cancers. The adjusted analyses showed an association of a higher cumulative cyclophosphamide dose (Odds ratio (OR) 1.09) and lower hydroxychloroquine dose (OR 0.93) with cancer risk in comparison with the controls.
A retrospective case-control study [27] included 40 011 patients with an ICD-9 coded diagnosis of primary autoimmune disease, 311 of which had a concomitant coded diagnosis of myelodysplastic syndrome or acute myeloid leukemia. Among the 86 patients who met inclusion criteria, 12 had SLE. Patients on azathioprine had an odds ratio of 7.05 for development of a myeloproliferative syndrome (P < 0.001). Methotrexate (OR 0.60), mercaptopurine (OR 0.62), and mycophenolate mofetil (OR 0.66) had favorable ORs that were not statistically significant. No association was found for anti-tumor necrosis factor agents.
Wadström et al. [28] examined the risk of cervical neoplasia in women with SLE in Sweden. There was an increased risk of cervical neoplasia in women with SLE compared with the general population (hazard ratio 2.12). The subcohort treated with immunosuppressants was at highest risk of cervical neoplasia, compared with those treated with antimalarials.
CARDIOVASCULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS
Hermassen et al. [29] in a nationwide, populationbased cohort study demonstrated a significantly higher risk of myocardial infarction (MI) and cardiovascular mortality in SLE patients with lupus nephritis compared with SLE patients without lupus nephritis ((hazard ratio 18.3 versus 2.2 for MI and hazard ratio 7.8 versus 1.6 for cardiovascular mortality). The higher risk of stroke in SLE was not significantly affected by the presence of lupus nephritis.
Using data from the Swedish National Patient Register, Arkema et al. [30] studied the occurrence of ischemic and hemorrhagic stroke in patients with SLE. The relative risk of ischemic stroke in SLE was more than doubled compared with the general population (hazard ratio 2.2), and importantly, the highest relative risks were observed within the first year after SLE diagnosis (hazard ratio 3.7).
To study ethnic differences in the cardiovascular risk among patients with SLE, Barbhaiya et al. [31] analyzed Medicaid data from 2000 to 2010 and identified 65 788 SLE patients: 93.1% were women and 42% were African American, 38% were Caucasia, 16% were Hispanic, 3% were Asian, and 1% were American Indian/Alaska Native. The risk of cardiovascular events was increased among African Americans (hazard ratio 1.14) compared with Caucasians, whereas Hispanics and Asians had a lower risk of MI (HR 0.61 and HR 0.57, respectively). Blacks and Hispanics had a higher risk of stroke (HR 1.31 and HR 1.22, respectively).
CONCLUSION
Over the past year, we have gained more insight into the worldwide incidence and prevalence of SLE. Data from the California Lupus Surveillance Project and the Manhattan Lupus Surveillance Program allowed estimation of incidence and prevalence among Hispanics and Asians who had a higher incidence and prevalence of SLE compared with Caucasians, but lower than African Americans. In Germany, the SLE incidence rate for German women was less than half of the French rate. A decline in the annual SLE incidence of 1.8% was observed in the United Kingdom, whereas in contrast the prevalence increased by 50% over a period of 15 years ending with 2012.
Despite advances in treatment, standardized mortality rates in SLE remain three times higher than in the general population. The risk of mortality is significantly increased for mortality due to renal disease, cardiovascular disease, and infection.
SLE is a risk factor for cervical neoplasia, in particular, for premalignant cervical lesions. The risk is highest among patients on immunosuppressants. Treatment-wise, azathioprine was shown to increase the risk of acute myeloid leukemia or myelodysplastic syndrome seven-fold in an autoimmune population, but the study included only a small number of SLE patients.
Lupus nephritis was shown to be an important cardiovascular risk factor with a hazard ratio nine times higher compared with SLE patients without lupus nephritis. SLE doubles the risk of stroke with the highest relative risk for stroke observed within the first year after diagnosis.
